A Film‐Forming System Hybridized with a Nanostructured Chloroacetamide Derivative for Dermatophytosis Treatment

Dermatophytosis is the fourth cause of infectious disease in the world, affecting about 40 % of the population. Thus, the prospection for new agents and the new formulations with antifungal potential is necessary. This study evaluated the anti‐dermatophytic activity of a nanostructure (NS) containing a chloroacetamide derivative (4‐BFCA‐NS) as well as its dose‐response kinetics and skin adhesive property when associated to a film‐forming system (4‐BFCA‐NS‐FFS), forming a hybrid. The dose‐response curves of 4‐BFCA‐NS and 4‐BFCA‐NS‐FFS were evaluated by time‐kill assay. A texture analyzer was used for evaluated the skin adhesive property of the formulations. NS presented a nanometric size, monomodal distribution, positive zeta potential, and slightly acidic pH. 4‐BFCA‐NS maintained the anti‐dermatophytic action of 4‐BFCA (MIC range 6.25–25 μg ml−1). 4‐BFCA‐NS‐FFS hybrid presented a fungicidal action and skin adhesive capacity, suggesting its applicability as a new topical formulation for the treatment of superficial and cutaneous dermatophytosis. Preparation of the nanostructured chloroacetamide derivative (4‐BFCA‐NS) and subsequent addition of pullulan and carbopol forming the hybrid: 4‐BFCA‐NS‐FFS for application on the skin. 4‐BFCA: N‐(4‐bromophenyl)‐2‐chloroacetamide. OP: organic phase. AP: aqueous phase.